

this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Claims:

Please substitute pending claims 1, 7, 16 and 21 with the following claims 1, 7, 16 and 21:

D1 Sub E1 1. (Twice Amended) A method of treatment or prevention of metastasis of cancer cells consisting essentially of administering to a patient in need of treatment a composition consisting essentially of an effective amount of an angiotensin, wherein said composition treats or prevents metastasis of cancer cells.

D2 Sub E2 7. (Twice Amended) A method of inducing the expression of β_1 integrin molecules in cancer cells consisting essentially of administering to a patient a composition consisting essentially of an effective amount of an angiotensin, wherein said composition induces the expression of β_1 integrin molecules in cancer cells.

D3 Sub E3 16. (Once Amended) A method of treatment or prevention of metastasis of

D3 cancer cells comprising administering to a patient in need of treatment an effective amount of an angiotensin, wherein said cancer cells are derived from at least one of the group consisting of skin, prostate, bone and cervix, wherein said method treats or prevents metastasis of cancer cells.

Sub E4
D4 21. (Once Amended) A method of inducing the expression of β_1 integrin molecules in cancer cells comprising administering to a patient an effective amount of an angiotensin, wherein said cancer cells are derived from at least one of the group consisting of skin, prostate, bone and cervix, wherein said method induces the expression of β_1 integrin molecules in cancer cells.
